Shares of Arcus Biosciences (RCUS) and Iteos Therapeutics (ITOS) surged Friday after Roche (RHHBY) provided "meaningful" evidence for a new cancer treatment…
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) – Equities researchers at HC Wainwright upped their Q2 2023 EPS estimates for shares of iTeos Therapeutics in a note issued to investors on Thursday, May 11th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($1.13) for the quarter, up […]
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) – Wedbush reduced their Q2 2023 EPS estimates for shares of iTeos Therapeutics in a note issued to investors on Wednesday, May 10th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.73) per share for the quarter, down from their prior estimate of ($0.58). Wedbush […]
10.05.2023 - – Belrestotug, formerly EOS-448, is advancing through multiple late-stage clinical trials including both doublet and triplet regimens – First-in-class program targeting a new mechanism of action in the adenosine pathway, EOS-984, is expected to . Seite 1
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) saw a large growth in short interest in March. As of March 31st, there was short interest totalling 1,690,000 shares, a growth of 11.2% from the March 15th total of 1,520,000 shares. Approximately 5.8% of the company’s stock are sold short. Based on an average trading volume of […]